Acromegaly
Understanding Acromegaly, also known as pituitary gigantism, requires accurate clinical documentation and medical coding. This resource provides information on Acromegaly diagnosis, ICD-10 codes, symptoms, treatment, and pituitary gland disorders for healthcare professionals. Learn about growth hormone excess, clinical manifestations of Acromegaly, and best practices for documenting patient care related to this rare condition.
Hormonal disorder causing excessive growth hormone, usually from a pituitary tumor.
Enlarged hands, feet, facial features, thickened skin, joint pain, excessive sweating.
Endocrinology clinics, pituitary centers, neurosurgery departments.
ICD-10 Code Families
Complete code families applicable to E22.0
When to use each related code
| Description | When to use |
|---|---|
| Overproduction of growth hormone in adults | Enlarged hands, feet, facial features in adults. Suspect pituitary adenoma. |
| Overproduction of growth hormone in children | Excessive growth in children. Rule out genetic causes. Consider pituitary involvement. |
| Growth hormone deficiency | Short stature in children, delayed puberty. Test GH levels. Exclude other causes. |
Best-practice checklist
- ✓Acromegaly diagnosis: Document growth hormone excess confirmation.
- ✓Acromegaly or Pituitary Gigantism: Note IGF-1 levels.
- ✓Document clinical features: enlarged extremities, facial changes.
- ✓Acromegaly: Detail pituitary imaging findings (MRI/CT).
- ✓Specify disease impact: cardiovascular, metabolic complications.
Common pitfalls to avoid
Coding acromegaly requires specifying active vs. inactive disease (E22.0 vs. E22.1) impacting reimbursement and quality metrics.
Confusing gigantism (childhood onset) with acromegaly (adult onset) leads to inaccurate coding and skewed growth hormone disorder data.
Insufficient documentation of the underlying cause (e.g., pituitary adenoma) can lead to coding errors and missed secondary diagnoses.
Best-practice tips
- 01Early diagnosis: GH/IGF-1 testing, MRI pituitary
- 02Optimize coding: ICD-10-CM E22.0, CPT 77003
- 03CDI: Document visual changes, soft tissue growth
- 04Compliance: Monitor treatment, document side effects
- 05Multidisciplinary care: Endocrinology, cardiology
Step-by-step checklist
- 1
Elevated IGF-1 level? (ICD-10 E22.0)
- 2
GH suppression after oral glucose? Document test details.
- 3
Pituitary imaging (MRI preferred)? Report findings.
- 4
Clinical features: enlarged hands/feet, coarse facial features? (SNOMED CT 268171004)
Ready-to-paste narrative
Patient presents with clinical manifestations suggestive of acromegaly, a rare hormonal disorder caused by excess growth hormone (GH) production. Symptoms reported include enlarged hands and feet, coarsened facial features, excessive sweating, joint pain, and carpal tunnel syndrome. Physical examination revealed prominent supraorbital ridges, prognathism, macroglossia, and widened spaces between teeth. The patient also reported headaches and visual disturbances, raising suspicion for pituitary adenoma, the most common cause of acromegaly. Biochemical evaluation will include serum insulin-like growth factor 1 (IGF-1) levels and an oral glucose tolerance test (OGTT) to suppress GH secretion. Imaging studies, such as MRI of the pituitary gland, will be performed to confirm the presence and assess the size of a potential pituitary adenoma. Differential diagnosis includes conditions such as familial tall stature and other causes of GH excess. Initial management will focus on symptom control and referral to an endocrinologist for further evaluation and discussion of treatment options, including transsphenoidal surgery, radiation therapy, and medical therapy with somatostatin analogs or GH receptor antagonists. Patient education regarding the long-term implications of acromegaly, including increased risk of cardiovascular disease, diabetes mellitus, and sleep apnea, will be provided. ICD-10 code E22.0 will be utilized for acromegaly and further codes will be added based on specific complications and comorbidities. CPT codes for laboratory and imaging studies will be documented accordingly. Follow-up appointments will be scheduled to monitor treatment response, manage complications, and optimize patient outcomes.
Common questions and answers
What are the most effective diagnostic tests for acromegaly in adults, differentiating it from other conditions causing tall stature or enlarged extremities?+
Diagnosing acromegaly in adults requires a multi-step approach to differentiate it from conditions like familial tall stature or Marfan syndrome. The first step involves measuring Insulin-like Growth Factor 1 (IGF-1) levels. Since IGF-1 is elevated in acromegaly, this test serves as an excellent initial screening tool. If IGF-1 is high, the next step is an oral glucose tolerance test (OGTT) with growth hormone (GH) measurements. In acromegaly, GH levels do *not* suppress during an OGTT, unlike in healthy individuals. Finally, magnetic resonance imaging (MRI) of the pituitary gland is essential to visualize the presence of a GH-secreting pituitary adenoma, confirming the diagnosis and aiding in treatment planning. Consider implementing these diagnostic steps sequentially to ensure accurate and timely diagnosis of acromegaly. Explore how our resources can assist you in interpreting these test results effectively.
How do I manage the long-term complications of acromegaly in my patients, specifically cardiovascular and metabolic issues, even after successful surgery?+
Even after successful surgical removal of the pituitary adenoma causing acromegaly, patients often require ongoing management of long-term complications, particularly cardiovascular and metabolic issues. Cardiovascular risks, including hypertension, cardiomyopathy, and arrhythmias, should be regularly screened for and aggressively managed using standard guidelines. Metabolic complications, such as insulin resistance, glucose intolerance, and type 2 diabetes, require careful monitoring and treatment with lifestyle modifications, metformin, and other anti-diabetic medications as needed. Regular follow-up with endocrinologists, cardiologists, and other specialists is crucial for optimizing long-term outcomes and minimizing morbidity. Learn more about the latest evidence-based recommendations for managing these complications and improving patient quality of life.
What are the different medical treatment options available for acromegaly besides surgery, and how do I choose the best approach for individual patient cases?+
When surgery isn't fully effective or feasible for managing acromegaly, several medical treatment options are available. Somatostatin analogs (SSAs), such as octreotide and lanreotide, are often the first-line medical therapy, effectively reducing GH and IGF-1 levels in many patients. Dopamine agonists, like cabergoline, can be beneficial in some cases, particularly for patients with mildly elevated hormone levels or as an adjunct to SSAs. Growth hormone receptor antagonists (GHRAs), such as pegvisomant, offer another option by blocking the effects of GH at the receptor level. The choice of the best medical approach depends on individual patient factors, including tumor size and characteristics, hormone levels, response to previous treatments, and patient preferences. Explore how a personalized approach, considering these factors, can lead to optimal outcomes in managing acromegaly.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.